The Third National Medicare Congress David B. Snow, Jr.

Slides:



Advertisements
Similar presentations
Medicare and Prescription Drugs: Issues for Employers and Consumers Robert D. Reischauer The Urban Institute National Health Policy Conference January.
Advertisements

Health Savings Accounts: Early Estimates Of National Take-Up Roger Feldman, Stephen T. Parente, Jean Abraham, Jon B. Christianson and Ruth Taylor
Challenges of Serving Low-income Medicare Beneficiaries: Impact of Cost Sharing Cindy Parks Thomas Brandeis University Schneider Institute for Health Policy.
Expanding Health Insurance Coverage James R. Tallon, Jr. President, United Hospital Fund Bipartisan Congressional Health Policy Conference January 13,
MEDICARE: PAST, PRESENT AND FUTURE James G. Anderson, Ph.D. Department of Sociology & Anthropology.
Medicare Part D: How Can You Assist Seniors in Your Life? Tim Jongerius, FSA, MAAA Sr. Actuary Wellmark Blue Cross Blue Shield of Iowa Iowa Actuaries Club.
Medicare and the New Prescription Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser.
Medicare Prescription Drug Coverage. What’s Different About Prescription Drug Information? One size does not fit all, more than ever before Distinct messages.
Figure 1 NOTE: Tests found no statistical difference from estimate for the previous year shown (p
MEDICARE PRESCRIPTION DRUG BENEFIT Presented by Juliette Cubanski, Ph.D. Principal Policy Analyst Medicare Policy Project The Henry J. Kaiser Family Foundation.
What’s in the Mail? Overview of Medicare Prescription Drug Coverage Beneficiary Communications Employer Forum Conference Call October 13, 2005.
MEDICARE PART D Are We Ready? Are We Ready?. Medicare Part D Overview Medicare Part A and B covers individuals Age 65 and older Age 65 and older Those.
There’s So Much More to Medicare, Let’s Talk Humana Medicare Advantage Health and Prescription Drug Plans M0006_GH210S6RR KC0906.
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy.
January National Medicare & You Training Program Amy Larrick, CMS NAACP April 27, 2006.
Medicare, Medicaid, and Health Care Reform Todd Gilmer, PhD Professor of Health Policy and Economics Department of Family and Preventive Medicine 1.
The New Medicare Prescription Drug Benefit: An Overview Prepared by: Michelle Kitchman, M.H.S. Kaiser Family Foundation For the: California Senate Health.
THE COMMONWEALTH FUND Medicare Part D: What Are The Concerns? Stuart Guterman Director, Program on Medicare’s Future The Commonwealth Fund Association.
0 Beneficiary Choices in Medicare Part D and Plan Features in 2006 Supported by PhRMA September 13, 2006.
Chartbook 2005 Trends in the Overall Health Care Market Chapter 1: Trends in the Overall Health Care Market.
1 Medicare Part D: Cost Management Issues Jack Hoadley Research Professor Georgetown University Health Policy Institute National Academy of Social Insurance.
Exhibit 1 NOTES: LIS is Low-Income Subsidy. PDP is prescription drug plan. MA-PD is Medicare Advantage Prescription Drug Plan. Analysis includes non-LIS.
"Helping Seniors Make Smart Decisions about their Drug Coverage Options" Hal Prink, FHFMA, Medicare Patient Advocate, Senior’s Voice for Healthcare Rights.
 2003 Medco Health Solutions, Inc. Implications of the New Medicare Prescription Drug Legislation for Pharmaceutical Manufacturers, PBMs and Health Plans.
MEDICARE’S 2006 TAKEOVER OF PRESCRIPTION DRUG COVERAGE FOR DUAL ELIGIBLES IN NURSING FACILTIES: ISSUES AND CONCERNS Jim Verdier Mathematica Policy Research,
1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.
PBMs, PDPs & MA-PDs: Which Way Is Up? Bob Atlas THE SECOND NATIONAL MEDICARE PRESCRIPTION DRUG CONGRESS November 1, 2005.
Third National Medicare Congress Marta Schroeder Divisional Vice President Public Health Policy & Strategy October 2006.
Aetna Inc. Smarter is Aetna’s retiree solutions. © 2011 Aetna Inc. XX.XX.XXX.X Month XX, 2011 Presenter Name.
Avalere Health LLC | The intersection of business strategy and public policy Enrollment in the Medicare Drug Benefit Medicare Congress Audioconference.
Avalere Health LLC | The intersection of business strategy and public policy The Impact of Enrollment in the Medicare Prescription Drug Benefit on Premiums.
The Third National Medicare Congress Marketplace Assessment of Drug Plan Options: MA-PDs and PDPs Scott G. Hughes R.Ph. October 17, 2006.
Health Reform: An Overview Unit 4 Seminar. The Decision The opinions spanned 193 pages, upholding the individual insurance mandate while reflecting a.
Medicare Open Enrollment For Coverage in 2016 Starts October 15, 2015 Ends December 7, MEDICARE Medicare.gov.
Overview of the Medicare Drug Benefit Presented by Tricia Neuman, Sc.D. Vice President and Director, Medicare Policy Project The Henry J. Kaiser Family.
A Summary of Insurance Coverage Chapter 2. 2 Overview Extent and nature of coverage Extent and nature of coverage Employer sponsored Employer sponsored.
1.03 Healthcare Finances.
Health Reform: What It Means to Our Community
Medicare Enrollment, NOTES: Numbers may not sum to total due to rounding. People with disabilities under age 65 were not eligible for Medicare.
1.03 Healthcare Finances.
Preparing for Health Reform: The Role of the Health Insurance Exchange
November 1, 2005 Cara M. Jareb, FSA
1.03 Healthcare Finances.
Total U.S. prescription drug spending, in $ billions:
Director, Pennsylvania PACE Program National Medicare Congress
Medicare Enrollment, NOTES: Numbers may not sum to total due to rounding. People with disabilities under age 65 were not eligible for Medicare.
Program strategies Government as predictable business partner
1.03 Healthcare Finances.
Lindy Hinman Avalere Health LLC
Part D Plan Perspective on Serving Dual Eligibles
1.03 Healthcare Finances.
Straight Talk for Seniors: How Will Health Care Reform Change Your Health Care? June 2013.
State Implementation of MMA
The Role of the Private Sector in Part D
Medicare and You John Williams SHIP Medicare Specialist
Medicare Part D: What Are The Concerns?
1.03 Healthcare Finances.
MEDICAID AND MMA ADMINISTRATIVE CHALLENGES: SPECIAL NEEDS PLANS
Discussion Topics History of Private Plans in Medicare
Will PBMs Participate in the New Medicare Prescription Drug Program
Jan Berger, M.D., M.J. Senior Vice President Chief Medical Officer
1.03 Healthcare Finances.
Medicare Rx Drug Benefit
Presented by Tricia Neuman, Sc.D.
Discussion Topics Factors Influencing Plan Participation
Medicare Prescription Drug Congress November 2, 2005 MMA Implementation: MMA Part D Long Term Care Implementation.
Medicare Reform: Implications for Pharmaceutical Manufacturers
1.03 Healthcare Finances.
Medicare Part D Implementation Issues: Key Decisions for States
Understanding Your Medicare Plan Options
Presentation transcript:

Business Strategy in the Medicare Market: The PBM Perspective October 16, 2006 The Third National Medicare Congress David B. Snow, Jr. Chairman & CEO, Medco Health Solutions, Inc

Medicare opportunity for PBMs doubles Medicare Part D creates new PBM market 2005 (42.0MM Lives, ~$120B) 2006 (43.1MM Lives, ~$133B) Market not served by PBMs Market served by PBMs Note: Enrollment estimates from Kaiser Family Foundation Medicare Chart Book, Summer 2005. Distribution from Medicare Advantage News, January 19, 2006. Employer Primary 2006 includes Federal Retiree Coverage (TRICARE, FEHB)

The Issues PBMs Considered: Public/Private Partnership? Stand Alone Fully Insured Drug Benefit? Underwriting Data? Pent up Demand? Will “The Tools” Survive? How to Motivate Dual Eligibles?

To Play or Not to Play GROW ~$45 Billion ~$60 Billion Average Annual PDP MAPD Employer Sponsored Medigap Medicare HMOs Discount Card 1985 2004 2006 ~$45 Billion Average Annual ~$60 Billion Average Annual ~$133 Billion Average Annual GROW PROTECT

Pre-Launch Anxiety and Uncertainty Will the benefit be a success? CMS Private industry is critical to success Will anyone participate? Will we need fallback plans? Will we be within budget projections? How do I best work with CMS and my business partners? What value do/could I add? How do I meet inevitable challenges? What capabilities must I build? What are my best alternatives? Who should I turn to for advice? What is Medicare Part D? Pharmacy Industry Employers Part D Beneficiaries

The Beneficiary Perspective: Overwhelming Market Choices 3000+ Part D options offered nationally 1,429 Prescription Drug Plans (PDPs) 458 Medicare Advantage (MA) plans 276 MA plans with Special Needs Plans Between 11 to 21 benefit options by region 10 National organizations covering 62% 4 “near-National” plans

What Did They Choose? 43.1 Million Lives No Known Source of Creditable Coverage Stand Alone PDP 10% 4.7 MM Estimated to Have Other Creditable Coverage1 24% 10.4 MM 13% 5.5 MM Total with Part D Drug Coverage: 22.5 MM (53%) 14% 6.1 MM Dual Eligibles Auto-enrolled into PDP 24% 10.4 MM Creditable Employer/Union Coverage2 14% 6.0 MM Medicare Advantage Drug Plan3 1 Includes Veterans Administration, Indian Health Service, employer plans without retiree subsidies, and employer plans for active workers. 2 Includes employer/union, FEHBP, and TRICARE coverage. 3 Approximately 594,000 dual-eligibles are enrolled in Medicare Advantage drug plans and are reported in this category. Source: HHS, April 20, 2006

The Launch: Implementation Challenges Public-private partnership begins to weaken Enrollment logic and delays, particularly among the low income membership in PDPs, lead to State intervention Consumer education challenges Customer service support Subsidy program – eligibility verification and reporting Politics begin to take a more significant role in the Medicare Part D benefit. Communications become uni-lateral, with over 300 year to date ‘directives’ and policy changes, most with significant process implications.

Making the public-private partnership work We all have similar interests: Choice and access for Medicare beneficiaries Member education and benefit understanding Cost management to ensure long term benefit sustainability Ease of benefit administration Program stability We can work together, similar to what was done when benefit was constructed, to make the benefit stronger.

Evolution of Medicare D Market Increasing focus on the individual

Premium Performance – 2006 vs Premium Performance – 2006 vs. 2007 Private Sector Competition leads to lower beneficiary cost -15.1%

Public-Private Partnership Model (The Larger Agenda) Non-MMA Participants $3650 pmpy1 MMA Participants $2878 pmpy >25% Reduction With 43.1M individuals participating in the MMA, annual pharmacy savings are ~$33B. What savings would be possible on the medical side if we eliminate the fiscal intermediary approach in favor of private sector competition? 1 Source: Medicare Trustees Report, CBO estimate of savings pmpy for beneficiaries participating vs. not-participating in Medicare Part D.